Ionis Pharmaceuticals has secured U.S. Food and Drug Administration approval for ZANVASTRO, or zilganersen, for pediatric and adult patients with Alexander disease, creating the first disease-modifying treatment for an ultra-rare neurological disorder that previously had no therapy directed at its underlying cause. ZANVASTRO is administered as a 50 mg intrathecal injection once every 12 weeks and is designed to reduce production of glial fibrillary acidic protein, or GFAP, whose toxic accumulation is central to Alexander disease. Ionis expects the medicine to become available in the United States within weeks and received a Rare Pediatric Disease Priority Review Voucher alongside the approval.
The approval also carries strategic significance for Ionis because ZANVASTRO becomes the company’s first independent commercial launch from its neurology pipeline and its second independent product launch during 2026. Ionis licensed zilganersen rights outside the United States to Recordati in June and says regulatory filings in Europe and Japan are expected in 2027. The commercial opportunity is necessarily small because Alexander disease occurs in only about one person per one million to three million worldwide, but the approval provides another important validation of antisense medicine in severe genetically defined neurological disease.
How much did ZANVASTRO change motor decline in the pivotal Alexander disease study?
The pivotal Phase 1-3 study enrolled 54 participants between 1.5 and 53 years old across 13 sites in eight countries. Participants were randomized 2:1 to zilganersen or control during a 60-week double-blind period, with the 50 mg dose evaluated as the pivotal regimen and administered every 12 weeks. Among patients aged five years and older, ZANVASTRO met the primary endpoint by producing statistically significant and clinically meaningful stabilization of gait speed on the 10-Meter Walk Test at week 61, with a least-squares mean difference of 33.3% compared with control and a p-value of 0.041.
The treatment signal extended beyond older children and adults. Ionis reported improvement in gross motor function among children aged two to four years using the Gross Motor Function Measure-88, while patient-, caregiver- and clinician-reported secondary and exploratory assessments generally favored ZANVASTRO. Because the disease is heterogeneous and the study population was small, longer follow-up will remain important for understanding how consistently these functional effects persist across different ages and disease stages.
Why is reducing GFAP different from treating Alexander disease symptoms?
Alexander disease is caused by pathogenic changes in the GFAP gene that lead astrocytes to overproduce and accumulate abnormal GFAP. Astrocytes provide essential support for neurons and myelin-producing cells, so progressive astrocyte dysfunction can ultimately damage multiple parts of the nervous system. Patients may develop worsening motor and cognitive function, swallowing problems, impaired airway protection and increasing dependence, while the disease can lead to death within roughly 14 to 25 years after symptom onset.
ZANVASTRO is an RNA-targeted antisense medicine intended to decrease synthesis of GFAP before excessive protein accumulates. That makes the therapy conceptually different from medicines used to control spasticity, seizures, feeding difficulties or other consequences after neurological damage has already occurred. The approval does not establish that treatment reverses established injury, but it creates the first FDA-authorized opportunity to intervene against a molecular driver of the disease itself.
What safety issues will clinicians need to monitor with ZANVASTRO?
Most adverse events in the clinical program were mild or moderate, and serious treatment-emergent adverse events occurred less frequently in the ZANVASTRO group than in the control group. The prescribing information nevertheless includes an important warning regarding aseptic meningitis, with one patient developing a serious event during the double-blind period that recurred during open-label treatment. Cerebrospinal-fluid white-cell and protein increases have also been observed, including nonserious events.
The most common adverse reactions occurring in at least 25% of treated patients and more frequently than control were vomiting, back pain, cough, headache and post-lumbar-puncture syndrome. Because the medicine is delivered intrathecally every three months, procedural tolerability and the ability to maintain long-term lumbar-puncture treatment are part of its real-world burden. Continued open-label extensions should help clarify whether safety remains stable as patients accumulate years of treatment.
Why is the approval important for antisense neurological drug development?
Ionis has spent decades building antisense platforms capable of selectively reducing or changing RNA associated with genetically driven diseases. The company has already been involved in neurological medicines including SPINRAZA for spinal muscular atrophy and QALSODY for SOD1-associated amyotrophic lateral sclerosis, while ZANVASTRO expands that approach into an astrocyte-driven leukodystrophy. The new approval reinforces a development strategy in which clearly defined genetic biology can sometimes support highly targeted drugs even when patient populations are exceptionally small.
The practical challenge is translating such scientific precision into reliable access. Ultra-rare disease diagnosis can be delayed, treatment centers are geographically concentrated and quarterly intrathecal administration requires specialized care. Ionis has created its Ionis Every Step support program to assist with education, insurance navigation and affordability, but actual uptake will depend on diagnosis, payer coverage and whether patients can reach centers able to administer the medicine safely.
What should families and neurologists watch after the FDA approval?
The most important clinical issue is durability. Patients completing the blinded study can continue through long-term extensions lasting several years, providing evidence on whether stabilization of walking and other functional benefits persists as Alexander disease would ordinarily continue progressing. Long-term data will also help establish whether treating younger patients earlier in their disease course produces different outcomes from beginning therapy after substantial neurological impairment has accumulated.
International regulatory expansion will be the other major milestone. Recordati controls development and commercialization outside the United States, with planned European and Japanese submissions in 2027. For an ultra-rare condition that previously had no disease-modifying medicine, those decisions will determine how broadly the first mechanistically targeted Alexander disease therapy becomes available beyond the small number of U.S. patients eligible for treatment.
